Celgene, Ionis ink China drug development pacts; Motif touts positive PhIII antibiotic data
A host of biotech startups in China have been making the trek to the US to partner on promising experimental therapies. And we have news …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
